Nicotine lactate | 14474-00-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Nicotine lactate
• 英文别名: 2-hydroxypropanoic acid;3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
• CAS: 14474-00-1
• 化学式: C13H20N2O3
• 分子量: 252.31
• InChiKey: VWTHFJXLFGINSW-PPHPATTJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  73.7
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] NICOTINE SALTS, CO-CRYSTALS, AND SALT CO-CRYSTAL COMPLEXES<br/>[FR] SELS, CO-CRISTAUX, ET COMPLEXES DE CO-CRISTAUX DE SELS DE NICOTINE
  申请人：REYNOLDS TOBACCO CO R

  公开号：WO2015183801A1

  公开（公告）日：2015-12-03

  The invention provides certain nicotine salts, co-crystals, and salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, nicotine salts with mucic acid, 3,5-dihydroxybenzoic acid, and 2,3-dihydroxybenzoic acid, and crystalline polymorphic forms of nicotine 4-acetamidobenzoate, nicotine gentisate, and nicotine 1-hydroxy-2-naphthoate are described. The invention further provides methods of preparation and characterization of such nicotine salts, co-crystals, and salt co-crystals and polymorphic forms thereof. In addition, tobacco products, including smoking articles, smokeless tobacco products, and electronic smoking articles comprising nicotine salts, co-crystals, and/or salt co-crystals are also provided.

  该发明提供了某些尼古丁盐、共晶和盐共晶，并提供了某些尼古丁盐的新颖多形态形式。具体来说，描述了与粘酸、3,5-二羟基苯甲酸和2,3-二羟基苯甲酸结合的尼古丁盐，以及尼古丁4-乙酰氨基苯甲酸、尼古丁吉替酸和尼古丁1-羟基-2-萘酸的结晶多形态形式。该发明还提供了制备和表征这些尼古丁盐、共晶和盐共晶以及其多形态形式的方法。此外，还提供了含有尼古丁盐、共晶和/或盐共晶的烟草制品，包括吸烟物品、无烟烟草制品和电子吸烟物品。
• NICOTINE SALTS, CO-CRYSTALS, AND SALT CO-CRYSTAL COMPLEXES
  申请人：R.J. Reynolds Tobacco Company

  公开号：US20150344456A1

  公开（公告）日：2015-12-03

  The invention provides certain nicotine salts, co-crystals, and salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, nicotine salts with mucic acid, 3,5-dihydroxybenzoic acid, and 2,3-dihydroxybenzoic acid, and crystalline polymorphic forms of nicotine 4-acetamidobenzoate, nicotine gentisate, and nicotine 1-hydroxy-2-naphthoate are described. The invention further provides methods of preparation and characterization of such nicotine salts, co-crystals, and salt co-crystals and polymorphic forms thereof. In addition, tobacco products, including smoking articles, smokeless tobacco products, and electronic smoking articles comprising nicotine salts, co-crystals, and/or salt co-crystals are also provided.

  本发明提供了某些尼古丁盐、共晶、盐共晶，并提供了某些尼古丁盐的新型多晶形式。具体而言，本发明描述了与粘酸、3,5-二羟基苯甲酸和2,3-二羟基苯甲酸共晶的尼古丁盐，以及尼古丁4-乙酰氨基苯甲酸盐、尼古丁吉替酸盐和尼古丁1-羟基-2-萘酸晶体多晶形式。本发明进一步提供了制备和表征这种尼古丁盐、共晶和盐共晶及其多晶形式的方法。此外，本发明还提供了含有尼古丁盐、共晶和/或盐共晶的烟草产品，包括吸烟物品、无烟烟草产品和电子吸烟物品。
• A CARTRIDGE FOR AN AEROSOL-GENERATING SYSTEM AND AN AEROSOL-GENERATING SYSTEM COMPRISING A CARTRIDGE
  申请人：Philip Morris Products S.A.

  公开号：EP3183979A1

  公开（公告）日：2017-06-28

  A cartridge (2, 102) for use in an aerosol-generating system, the cartridge comprises: an elongate first compartment (10, 110) having a length L1 and a maximum transverse cross-sectional area A1, the first compartment having a first air inlet (20, 120) and a first air outlet (26, 126) and containing a nicotine source comprising a first carrier material (12, 112) loaded with between about 1 milligram and about 50 milligrams of nicotine; and an elongate second compartment (14, 114) having a length L2 and a maximum transverse cross-sectional area A2, the second compartment having a second air inlet (22, 122) and a second air outlet (28, 128) and containing an acid source. The first compartment and the second compartment are arranged in parallel within the cartridge and the ratio (L1)2:A1 is at least about 12:1 and the ratio (L2)2:A2 is at least about 12:1. An aerosol-generating system (200) comprises: the cartridge (102); and an aerosol-generating device (202) comprising: a housing (206) defining a cavity (208) for receiving at least a portion of the cartridge; and a heater for heating the first compartment and the second compartment of the cartridge.

  一种用于气溶胶产生系统的滤芯（2，102），滤芯包括一个细长的第一隔室（10，110），具有长度 L1 和最大横截面积 A1，第一隔室具有第一进气口（20，120）和第一出气口（26，126），包含尼古丁源，尼古丁源包括第一载体材料（12，112），尼古丁含量在 1 毫克到 50 毫克之间；以及一个细长的第二隔室（14，114），其长度为 L2，最大横截面积为 A2，第二隔室具有第二进气口（22，122）和第二出气口（28，128），并含有酸源。第一隔室和第二隔室在滤芯内平行布置，比率（L1）2:A1 至少约为 12:1，比率（L2）2:A2 至少约为 12:1。气溶胶产生系统 (200) 包括：墨盒 (102)；以及气溶胶产生装置 (202)，其中包括：外壳 (206) ，该外壳限定了一个空腔 (208)，用于接收墨盒的至少一部分；以及加热器，用于加热墨盒的第一隔室和第二隔室。
• METHOD OF MAKING A ROD FOR USE AS AN AEROSOL-FORMING SUBSTRATE HAVING CONTROLLED POROSITY DISTRIBUTION AND HEATED AEROSOL-GENERATING ARTICLE COMPRISING THE ROD
  申请人：Philip Morris Products S.A.

  公开号：EP3281535A1

  公开（公告）日：2018-02-14

  There is provided a heated aerosol-generating article comprising a plurality of elements including an aerosol-forming substrate assembled within a wrapper, the aerosol-forming substrate being in the form of a rod having a diameter of between 6.5 mm and 8.5 mm. The rod is formed from a crimped and gathered sheet of aerosol-forming material, for example homogenised tobacco material, the sheet having a width of between 110 mm and 160 mm, a thickness of between 200 micrometres and 230 micrometres, and the sheet being crimped with a crimping depth of between 100 and 250 micrometres.

  提供了一种加热气溶胶生成物，它由多个元件组成，包括组装在包装纸内的气溶胶形成基板，气溶胶形成基板呈棒状，直径在 6.5 毫米到 8.5 毫米之间。杆由气溶胶形成材料（例如均质烟草材料）的卷曲和聚集的薄片形成，薄片的宽度在 110 毫米到 160 毫米之间，厚度在 200 微米到 230 微米之间，薄片的卷曲深度在 100 微米到 250 微米之间。
• EXCIPIENTS FOR NICOTINE-CONTAINING THERAPEUTIC COMPOSITIONS
  申请人：Modoral Brands Inc.

  公开号：EP3744313A1

  公开（公告）日：2020-12-02

  A composition intended to be employed for therapeutic purposes incorporates an active ingredient (e.g., a source of nicotine) and at a non-active ingredient that is carried by a porous substrate. The non-active ingredient can be a substance that has the capability of affecting the pH of the biological system to which it is applied (e.g., basic substance and/or buffering agent is sorbed onto the porous carrier, so as to be in intimate contact with that carrier). Representative forms of nicotine include free base (e.g., as a mixture of nicotine and microcrystalline cellulose), a nicotine salt (e.g., as nicotine bitartrate) and nicotine polacrilex. The basic substance can be sodium carbonate, and the porous substrate can be microcrystalline cellulose. The composition is useful for treatment of central nervous system conditions, diseases, and disorders, and can be used as a nicotine replacement therapy.

  一种用于治疗目的的组合物包含一种活性成分（如尼古丁源）和一种由多孔基质承载的非活性成分。非活性成分可以是一种能够影响生物系统 pH 值的物质（例如，碱性物质和/或缓冲剂被吸附在多孔载体上，从而与载体紧密接触）。具有代表性的尼古丁形式包括游离碱（如尼古丁和微晶纤维素的混合物）、尼古丁盐（如酒石酸尼古丁）和多糖尼古丁。基本物质可以是碳酸钠，多孔基质可以是微晶纤维素。该组合物可用于治疗中枢神经系统病症、疾病和失调，并可用作尼古丁替代疗法。